Trade Emergent BioSolutions Inc. - EBS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.81 |
| Open | 8.98 |
| 1-Year Change | 335.92% |
| Day's Range | 8.82 - 9.72 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | 8.81 | 0.68 | 8.36% | 8.13 | 8.94 | 8.11 |
| Nov 19, 2024 | 8.18 | -0.03 | -0.37% | 8.21 | 8.52 | 8.17 |
| Nov 18, 2024 | 8.57 | 0.44 | 5.41% | 8.13 | 8.63 | 7.72 |
| Nov 15, 2024 | 7.68 | -1.31 | -14.57% | 8.99 | 9.03 | 7.68 |
| Nov 14, 2024 | 9.23 | -0.62 | -6.29% | 9.85 | 9.92 | 9.22 |
| Nov 13, 2024 | 9.94 | -0.79 | -7.36% | 10.73 | 10.95 | 9.90 |
| Nov 12, 2024 | 10.85 | -0.64 | -5.57% | 11.49 | 11.50 | 10.58 |
| Nov 11, 2024 | 11.89 | -0.14 | -1.16% | 12.03 | 12.54 | 11.76 |
| Nov 8, 2024 | 11.70 | 0.84 | 7.73% | 10.86 | 12.03 | 10.58 |
| Nov 7, 2024 | 10.99 | -0.38 | -3.34% | 11.37 | 12.66 | 10.92 |
| Nov 6, 2024 | 9.17 | -0.09 | -0.97% | 9.26 | 9.40 | 8.86 |
| Nov 5, 2024 | 8.93 | 0.31 | 3.60% | 8.62 | 9.01 | 8.35 |
| Nov 4, 2024 | 8.75 | -0.14 | -1.57% | 8.89 | 9.19 | 8.62 |
| Nov 1, 2024 | 9.10 | 0.10 | 1.11% | 9.00 | 9.39 | 8.92 |
| Oct 31, 2024 | 9.01 | -0.41 | -4.35% | 9.42 | 9.53 | 8.93 |
| Oct 30, 2024 | 9.61 | 0.40 | 4.34% | 9.21 | 9.85 | 9.15 |
| Oct 29, 2024 | 9.30 | -0.19 | -2.00% | 9.49 | 9.65 | 9.12 |
| Oct 28, 2024 | 9.59 | 0.70 | 7.87% | 8.89 | 9.65 | 8.89 |
| Oct 25, 2024 | 8.90 | -0.07 | -0.78% | 8.97 | 9.14 | 8.71 |
| Oct 24, 2024 | 9.03 | 0.28 | 3.20% | 8.75 | 9.10 | 8.59 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Emergent BioSolutions Company profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.| Industry: | Pharmaceuticals (NEC) |
400 Professional Dr, Suite 400
GAITHERSBURG
MARYLAND 20879
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com